18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma

AIDS Patient Care and STDs

Volumn 22, Issue 9, 2008, Pages 695-700

  Just, Pierre Alexandre ^a,b   Fieschi, Claire ^a   Baillet, Georges ^a,b   Galicier, Lionel ^a   Oksenhendler, Eric ^a   Moretti, Jean Luc ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; ESOPHAGITIS; ESOPHAGUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMAGE RECONSTRUCTION; LUNG; LYMPH NODE METASTASIS; MALE; PAROTID GLAND; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; B CELL LYMPHOMA; LYMPH NODE; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADULT; BURKITT LYMPHOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 51849152460     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0174     Document Type: Article

References (22)

1. Remick SC. Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. Cancer Control 1995;2:97-103.
2. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412-426.
3. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-3020.
4. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
5. Jhanwar YS, Straus DJ. The role of PET in Lymphoma. J Nucl Med 2006;47:1326-1334.
6. Gorospe L, Raman S, Echeveste J, et al. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients. Nucl Med Commun 2005;26:671-687.
7. Barrington SF, Carr R. Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. Clin Oncol (R Coll Radiol)1995;7:334-335.
8. Yokohama A, Tsukamoto N, Uchiumi H, et al. Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma. Ann Hematol 2004;83:120-123.
9. Pan MH, Chang YL, Wu YW, Kao CH, Yen RF. Gallium-67 scintigraphy and f-18 fluorodeoxyglucose position emission tomography in posttransplant lymphoproliferative disorder. Clin Nucl Med 2004;29:329-331.
10. Chander S, Webster GC, Zingas AP, et al. American Burkitt's lymphoma of the head and neck: evaluation with serial FDG-PET. Clin Nucl Med 2004;29:646-648.
11. Kyoung Jung H, Kim EK, Yun M, Jung Kim M, Young Kwak J. Bilateral breasts involvement in Burkitt's lymphoma detected only by FDG-PET. Clin Imaging 2006;30:57-59.
12. Garber K. Energy deregulation: Licensing tumors to grow. Nature 2006;312:1158-1159.
13. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997;38:1575-1583.
14. Magrath IT, Venkatesh H, Gascoyne RD. Burkitt's lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Lee Harris N, eds. Non-Hodgkin's Lymphomas. Philadelphia: Lippincott Williams & Wilkins, 2004:477-501.
15. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005;106:1376-1381.
16. 18F-FDG PET in malignant lymphoma: Significance of positive findings. Eur J Nucl Med Mol Imaging 2005;32:749-756.
17. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688.
18. Han HS, Escalon MP, Serafini A, et al. High incidence of false positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens [abstract]. Blood (ASH Annual Meeting Abstracts) 2006;108:2401.
19. Juweid M, Stroobants S, Mottaghy F, et al. Recommandations of the imaging committee of the International Harmonization project (IHP) for FDG-PET (PET) use in patients with lymphoma [abstract]. Eur J Nucl Med 2006;33(Suppl 2):S86.
20. Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-1839.
21. Alinari L, Ambrosini V, Castellucci P, et al. Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients. Leuk Lymphoma 2006;47:1048-1052.
22. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30(Suppl 1):S117-127.